Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 487

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Dr Paolo Ghia presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the ASCEND study.

Patients with relapsed or refractory chronic lymphocytic leukaemia were randomised to receive either acalabrutinib or the investigator choice of rituximab plus idelalisib (IdR) with acalabrutinib showing a much improved PFS and safety profile.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation